News from biopharmx corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 20, 2019, 16:05 ET BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology...


Sep 09, 2019, 08:15 ET BioPharmX Reports Fiscal Second Quarter 2020 Financial Results and Provides Corporate Update

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


Jul 16, 2019, 16:15 ET BioPharmX Announces Steven M. Bosacki Joins the Company as Chief Operating Officer

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


Jun 25, 2019, 07:30 ET BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


Jun 11, 2019, 16:10 ET BioPharmX Reports Fiscal First Quarter 2020 Financial Results

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


May 22, 2019, 08:10 ET BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products,...


Apr 26, 2019, 07:30 ET BioPharmX Completes 1-for-25 Reverse Stock Split

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology...


Apr 15, 2019, 16:15 ET BioPharmX Announces Reverse Stock Split

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology...


Mar 21, 2019, 08:55 ET BioPharmX Announces $3.9 Million Offering

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


Mar 18, 2019, 06:45 ET BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


Mar 14, 2019, 16:05 ET BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


Mar 04, 2019, 06:00 ET BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


Feb 27, 2019, 16:15 ET BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology...


Feb 04, 2019, 07:00 ET BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


Dec 20, 2018, 16:30 ET BioPharmX Receives Notice of Noncompliance from NYSE American

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products,...


Dec 06, 2018, 16:10 ET BioPharmX Reports Third Quarter 2019 Financial Results

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today...


Nov 16, 2018, 06:00 ET BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market,...


Oct 11, 2018, 16:30 ET BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that...


Sep 28, 2018, 09:15 ET BioPharmX Receives Notice of Noncompliance from NYSE American

BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market,...


Sep 12, 2018, 17:30 ET BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the...


Aug 30, 2018, 16:15 ET BioPharmX Reports Second Quarter 2019 Financial Results

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today reports...


Aug 14, 2018, 18:00 ET BioPharmX Announces Results of Annual Shareholders Meeting

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today held its 2018...


Aug 09, 2018, 06:15 ET BioPharmX Announces Patent Award, Expanding Protection for Innovations in Solid Dosage Forms

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that...


Jul 31, 2018, 09:15 ET BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of Rosacea

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced it...


Jul 19, 2018, 09:15 ET BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that...